C6528 H10072 N1732 O2042 S42
Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer
Vedolizumab is in Phase 2 development for HIV treatment.
(Compound details obtained from ChemIDplus Advanced,1 Treatment Action Group website,2 and Entyvio Full Prescribing Information3)
What is vedolizumab?
Vedolizumab (brand name: Entyvio) is currently approved by the U.S.(FDA) to treat ulcerative and Crohn’s disease.3 Vedolizumab is also being studied as an to treat HIV .4,5
As an investigational HIV drug, vedolizumab belongs to a group of drugs called α₄β₇ integrin antagonists. α₄β₇ integrin antagonists block an immune cellcalled α₄β₇.3 The α₄β₇ receptor is thought to have an important role in directing HIV into gut tissues.6
Researchers are currently studying whether vedolizumab can help people with HIV maintain control of theirlevels.4,5
Which clinical trials are studying vedolizumab?
Study Name: NCT03577782
Status: The status of this study is unknown.
Purpose: The purpose of this study is to evaluate whether vedolizumab plus (ART) can help people who have never taken HIV medicines control their viral load levels during a of ART.4
Study Names: HAVARTI; NCT03147859
Status: This study is currently recruiting participants.
Purpose: The purpose of this trial is to evaluate vedolizumab’s safety and ability to control viral load levels in individuals with undergoing a structured treatment interruption of ART.5
Study Names: EHVA T02/ANRS VRI07; NCT04120415
Status: See the ClinicalTrials.gov record for this study’s status.
Location: Not available
Purpose: The purpose of this study is to evaluate the ability of vedolizumab given with and without the MVA HIV-B in controlling viral load levels in people undergoing a structured treatment interruption of ART.7
A Phase 1 study (NCT02788175) evaluating the effectiveness of vedolizumab on controlling in individuals undergoing a structured treatment interruption of ART has also been completed.8
For more details on the studies listed above, see the Health Professional version of this drug summary.
What side effects might vedolizumab cause?
One goal of HIV research is to identify new drugs that have fewer side effects. In the Phase 2 HAVARTI trial (NCT03147859), eight adults with HIV received infusions of vedolizumab. Vedolizumab was administered both before and after a structured treatment interruption of ART. No drug-related severe side effects were reported. Influenza and severe each occurred in one participant.5,9
Because vedolizumab is still being studied, information on possible side effects of the drug is not complete. As testing of vedolizumab continues, additional information on possible side effects will be gathered.
Additional information on side effects known to be associated with vedolizumab can be found in the FDA-approved Full Prescribing Information for Entyvio.
Where can I get more information about clinical trials studying vedolizumab?
More information about vedolizumab-related research studies is available from.
Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a NIH Clinical Research Trials and You.is right for you. For more information, visit
- United States National Library of Medicine. ChemIDplus Advanced: Vedolizumab. https://chem.nlm.nih.gov/chemidplus/rn/943609-66-3. Accessed March 1, 2021
- Treatment Action Group website. Research toward a cure trials. https://www.treatmentactiongroup.org/cure/trials. Accessed March 1, 2021
- Takeda Pharmaceuticals America, Inc. Entyvio: full prescribing information, November 12, 2020. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c. Accessed March 1, 2021
- Hospitales Universitarios Virgen del Rocío. Phase II clinical trial to analyze the safety and efficacy of vedolizumab combined with antiretroviral therapy to achieve permanent virological remission in HIV-infected subjects without previous antiretroviral therapy. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 12, 2018. NLM Identifier: NCT03577782. https://clinicaltrials.gov/ct2/show/NCT03577782. Accessed March 1, 2021
- Ottawa Hospital Research Institute. Vedolizumab treatment in antiretroviral drug treated chronic hiv infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 3, 2017. NLM Identifier: NCT03147859. https://clinicaltrials.gov/ct2/show/NCT03147859. Accessed March 1, 2021
- Uzzan M, Tokuyama M, Rosenstein AK, et al. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals. Sci Transl Med. 2018;10(461). doi:10.1126/scitranslmed.aau4711
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: a Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic Infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 30, 2019. NLM Identifier: NCT04120415. https://www.clinicaltrials.gov/ct2/show/NCT04120415. Accessed March 1, 2021
- National Institute of Allergy and Infectious Diseases (NIAID). An exploratory, open-label study of vedolizumab (anti-alpha4beta7 antibody) in subjects with HIV infection undergoing analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 28, 2016. NLM Identifier: NCT02788175. https://clinicaltrials.gov/ct2/show/NCT02788175. Accessed March 1, 2021
- McGuinty M, Angel J, Kumar A, et al. Seeking suppression in HAVARTI: viremia & T cells after vedolizumab & ATI in HIV/ART. Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2019; Seattle, WA. Poster 393. https://2jg4quetidw2blbbq2ixwziw-wpengine.netdna-ssl.com/wp-content/uploads/sites/2/posters/2019/1430_McGuinty_0393.pdf. Accessed March 1, 2021
Last Reviewed: March 1, 2021